Nerofe™
A Breakthrough in Oncology
Immune System Key (ISK) — a Jerusalem clinical-stage oncology company (founded 2005) developing Nerofe™, a first-in-class 14-amino-acid human peptide that simultaneously targets all three core cancer pathways: angiogenesis inhibition, immune activation and direct tumor-cell killing.
The world’s only drug simultaneously active across all three cancer pathways via the ST2/T1 receptor — a target no one has exploited before.
FDA
Orphan Drug · 7-yr exclusivity
Phase IIa
Active Clinical Stage
7
Worldwide Patents
$20–25M
Series A Target
Behind the acronyms lies a rare opportunity: an Israeli company that developed a globally unique mechanism of action against one of the most lethal cancers. With zero dose-limiting toxicities in Phase I, FDA Orphan Drug status, and 7 worldwide patents — this is not a research gamble, but an advanced scientific asset at an inflection point toward significant commercial value.
The Company & Platform
ISK is a clinical company developing novel drugs based on the discovery of new genes encoding novel human peptide hormones. These genes are encoded in 95% of the human genome — a region where scientists have until now lacked the tools to search for new genes. Using a unique AI technology, ISK discovers new genes and applies them in successful clinical trials — to treat cancer, metabolic and neurodegenerative diseases.
AI Genome — The Core Technology
A deterministic AI genomic technology that reads any genome — human or animal — and searches for new peptide-hormone genes, receptors and enzymes, based on matching 3D structures to DNA sequences ("thinking outside the box").
The Unmet Need & Our Solution
❌ The Problem — AML
✓ 5-year survival: only 30%
✓ Fewer than 30% of patients respond
✓ Near-universal treatment resistance
✓ No ST2/T1 target in any existing therapy
✅ The Solution — Nerofe™
✓ 14-amino-acid human peptide
✓ Simultaneous action on 3 cancer pathways
✓ ST2/T1 receptor — unique worldwide
✓ Zero DLTs in Phase I · validated biomarker · 2 US site
7 Core Advantages
01
Phase IIa
Active
Past IND · zero DLTs in Phase I · validated biomarker
02
First-in-Class Mechanism
ST2/T1 receptor — no competitive overlap worldwide
03
FDA Orphan Drug
AML: 7-year exclusivity + accelerated review
04
Capital
Efficiency
$4.2M grants reached Phase IIa — near-zero dilution
05
Strong
Exit
Forma→Novo $1.1B · Trillium→Pfizer $2.3B · IRR 35–60%
06
Expanding Pipeline
KRAS (Phase 1) · TNBC · Neurodegenerative (Harvard/MGH)
07
World-Class Partnerships
J&J JLABS · Harvard/MGH · Georgetown · Sylvester
BRIDGES B2B
